Explained: Why a decade-long trial to prevent Alzheimer’s failed, and what that means | Explained News,The Indian Express
The decade-long effort was the first time that a clinical trial for the disease focused on people who were genetically predisposed to Alzheimer’s, but did not have any symptoms yet.
An experimental Alzheimer’s drug aimed at slowing or preventing cognitive decline in people has failed a clinical trial, landing a blow to efforts to find a solution to fight back against the neurodegenerative disease. What was the trial, why is the failure a significant blow?
Why was the trial closely watched?
The decade-long effort was the first time that a clinical trial for the disease focused on people who were genetically predisposed to Alzheimer’s, but did not have any symptoms yet. The study, according to the New York Times, involved people from an extended family in Columbia. Around 1,200 members of this extended family of 6,000 had a specific gene mutation that is a guarantee of developing the diseases. The drug on test was crenezumab, made by Roche group’s Genentech.
How did the trial work?
The aim was to start therapy early and to keep this type of Alzheimer’s – driven by a single gene mutation – in check. So, around 169 members of the family with the gene mutation were given the trial drug ‘crenezumab’ or a placebo, while 83 who had no gene mutation were just given the placebo. But after the lengthy trial, drug maker Roche announced on Thursday that the results were disappointing and did not show “significant clinical benefits”.